1 / 30

SMALL CELL LUNG CANCER 2007

SMALL CELL LUNG CANCER 2007. BP HIGGINS MD FRCPC CFPRCC. SMALL CELL LUNG CANCER. DECLINING INCIDENCE 15% RAPIDLY PROLIFERATING TUMOR CHEMOTHERAPY SENSITIVE CENTRAL ENDOBRONCHIAL LESION (SUBMUCOSAL). SMALL CELL. NEUROENDOCRINE DIFFERENTIATION

cianna
Télécharger la présentation

SMALL CELL LUNG CANCER 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SMALL CELL LUNG CANCER 2007 BP HIGGINS MD FRCPC CFPRCC

  2. SMALL CELL LUNG CANCER • DECLINING INCIDENCE 15% • RAPIDLY PROLIFERATING TUMOR • CHEMOTHERAPY SENSITIVE • CENTRAL ENDOBRONCHIAL LESION (SUBMUCOSAL)

  3. SMALL CELL • NEUROENDOCRINE DIFFERENTIATION • SPECTRUM CARCINOID-ATYPICAL CARCINOID-SMALL CELL • IHC KERATIN+ CD56+ TTF1+ SYNAPTOPHYSIN+

  4. STAGING • LIMITED :TUMOR THAT CAN BE ENCOMPASSED WITHIN A SINGLE REASONABLE RADIATION PORT 1/3 • EXTENSIVE :ALL THE REST 2/3

  5. STAGING • CBC BIOCHEMICAL PROFILE(LDH) • CT THORAX(LIVER/ADRENALS) • BONE SCAN • CT/MRI BRAIN

  6. TREATMENT • LIMITED DISEASE • ETOPOSIDE/CISPLATIN (GIVE CISPLATIN FIRST) E 100mg/m2 x3d Cisplatin 25mg/m2 x 3d q 21d x 6 cycles

  7. TREATMENT • EVANS JCO 1985 CAV vs CAV/EP MEDIAN SURVIVAL 8.0 vs 9.6 m • ROTH JCO 1992 CAV vs CAV/PE vs EP MEDIAN SURVIVAL 8.3 vs 8.1 vs 8.6 m

  8. Sundstrom et al. JCO 2002

  9. TREATMENT • 2 META-ANALYSES DEMONSTRATE SUPERIORITY OF CISPLATIN CONTAINING REGIMENS • MULTI-DAY CHEMOTHERAPY • 5HT3 ANTAGONISTS • HYPOTENSION WITH ETOPOSIDE • ?CARBOPLATIN? Extensive Disease Skarlos Ann Onc 1994 EC vs EP MEDIAN SURVIVAL 11.8 vs 12.5 m

  10. TREATMENT LIMITED SCLC • THORACIC RADIATION • ?CONCURRENT vs SEQUENTIAL • PATIENT SELECTION : GOOD PS, AGE, SEX

  11. RADIATIONJCO 1992 Warde & Payne

  12. TIMING OF RADIATIONNCIC BR-5 JCO 1993 Murray,N

  13. RADIATION • JCO 2004 META-ANALYSIS~SMALL BUT SIGNIFICANT BENEFIT IN 2 y SURVIVAL IN FAVOUR OF EARLY RADS(<9 WEEKS) ORR 1.17 p=0.03 • ?HYPERFRACTIONATION? (ESOPHAGITIS/INCONVENIENCE)

  14. PROPHYLACTIC CRANIAL IRRADIATION (PCI) • 5.4% IMPROVEMENT IN 3 YEAR SURVIVAL. NEJM 1999 • NEUROPSYCHOLOGIC TOXICITY(MEMORY LOSS) • ATAXIA • FOR COMPLETE RESPONDERS/ EXCELLENT PR • INCIDENCE ~20% AT DIAGNOSIS >50% AT 2 YEARS • ?EXTENSIVE DISEASE

  15. ASCO 2007

  16. ASCO 2007

  17. ASCO 2007

  18. EXTENSIVE SCLCNCIC BR8 JCO 1999 MURRAY,N et al.

  19. EXTENSIVE SCLC • IP vs EP NEJM 2002 n=154 • Median Survival 12.8 m vs 9.4 m 2y Survival 19.5% vs 5.2% • JCO 2006 Hanna et al. n=331 • IP vs EP RR 48 vs 43.6% MS 9.3 vs 10.2 mos Diarrhea vs Neutropenia

  20. Fig 2. Overall survival Hanna, N. et al. J Clin Oncol; 24:2038-2043 2006

  21. Fig 1. Kaplan-Meier estimates for survival in the intent-to-treat population Eckardt, J. R. et al. J Clin Oncol; 24:2044-2051 2006

  22. SECOND LINE Rx • IMPORTANCE OF PROGRESSION FREE INTERVAL • <3mos,>6-12mos • Patient selection • MEDIAN SURVIVAL 2-3mos

  23. SECOND LINE Rx • JCO 1999 CAV vs Topotecan • Median survival 25 weeks • 1 year survival 14% • (selection!!!!!!!!) • If long DFI consider original regimen • Patient convenience,$

  24. SCLC PARANEOPLASTIC SYNDROMES • ACTH 3-7% • ADH 3-15% • LAMBERT-EATON • CEREBELLAR DEGENERATION • NOT HPOA!!!! • SVC OBSTRUCTION • Rx UNDERLYING DISEASE

  25. LIMITED DISEASE EP/RADS RR 65-90% CR 40-75% Median survival 18-24mos 5 y survival 20-25% EXTENSIVE DISEASE EP/ECARBO/E RR 60-85% CR 15-30% Median survival 6-11mos 5 y survival <2% EJ CANCER 2004 SCLC SUMMARY

  26. SCLC • No Role for DI/DD • 2 Drugs = 3 or more • Cisplatin based • 4 cycles in ED • ? Targeted Rx ?

More Related